Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Co-creating patient partnership within a national cancer trials network: Experience from Cancer Trials Ireland in partnership with the Irish Cancer Society.

Emer Mulvaney, Patrick Kivlehan, Claire Kilty et al. Jun 01, 2026 pp. 11061-11061 10.1200/jco.2026.44.16_suppl.11061

11061 Background: Structured patient partnership is increasingly recognised in oncology research, yet less is known about...

Understanding palliative care gaps in young adult ovarian cancer: A population-based study of 37,880 hospitalizations.

Rigved Virendra Jeurkar, Aishwarya Ramesh, Kamleshun Ramphul et al. Jun 01, 2026 pp. 5557-5557 10.1200/jco.2026.44.16_suppl.5557

5557 Background: Palliative care (PalC) improves both quality of life and survival compared to usual care. Despite this, s...

Effects of prophylactic fibrin glue on post-gastric ESD bleeding in gastric neoplasm: A meta-analysis of randomized controlled trials.

Faiza Khalid, Raj Nandan Chennuri, Adithya Chandran et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16148

e16148 Background: Post-procedural bleeding remains a significant complication following gastric endoscopic submucosal dis...

<i>CCND1</i> amplification and breast cancer–specific survival in estrogen receptor–positive, HER2-negative disease.

Regan Laird, Mia Wallach Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12723

e12723 Background: Amplification of Cyclin D1 ( CCND1 ) is common in estrogen rece...

Outcomes following surgery versus non-surgical management for gallbladder cancer patients presenting with jaundice: A systematic review and meta-analysis.

Amit Kumar Kumar Mishra Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16230

e16230 Background: Gallbladder cancer (GBC) presenting with obstructive jaundice typically indicates advanced disease and...

National trends for cervical cancer–related mortality rates from 1999-2020: A National Inpatient Sample–based analysis.

Hafiz Aqib Ilyas Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17517

e17517 Background: Cervical cancer is a malignant epithelial tumor that forms in the cervix of the uterus, caused primaril...

Distinct immunologic vs progenitor landscapes in myeloid leukemia recurrence: Adaptive immune persistence in pediatrics vs niche exhaustion in adults.

Karen Dong-Tran, Thomas Noonan, Neil Arya Babu et al. Jun 01, 2026 pp. 10021-10021 10.1200/jco.2026.44.16_suppl.10021

10021 Background: Recurrent myeloid leukemia remains a therapeutic challenge with distinct clinical trajectories across ag...

A National Cancer Database analysis of hepatoid adenocarcinoma: Epidemiology, socioeconomic, and clinical factors.

Alena Gagnon, Tran Van Khanh Pham, Akaash Surendra et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20767

e20767 Background: Hepatoid adenocarcinoma (HAC) is a rare extrahepatic neoplasm that displays histologic similarity to he...

Influence of a vertically integrated care system on mortality risks in insured patients by socio-economic status.

Robert Michael Cooper, Deborah Ling Grant, Jing Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13560

e13560 Background: Vertically integrated health care delivery systems may help reduce disparities in cancer outcomes due t...

Second-line cetuximab monotherapy following PD-1 inhibitor treatments in patients with recurrent/metastatic head and neck carcinoma.

Mercedes Porosnicu, Thomas William Lycan, Mark Chang et al. Jun 01, 2026 pp. 6055-6055 10.1200/jco.2026.44.16_suppl.6055

6055 Background: PD-1 inhibitors, alone or in combination with chemotherapy, are standard first-line therapy for recurrent...

Characterization and clinical impact of temozolomide-induced hepatotoxicity in <i>IDH</i> -wild type glioblastoma: A comprehensive analysis of injury patterns, CTCAE grade transitions, and survival outcomes.

Gözde Savaş, Sumeyye Zehra Erol, Imdat Eroglu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14075

e14075 Background: Temozolomide (TMZ) is the cornerstone of glioblastoma (GBM) treatment but is associated with potential...

Inpatient palliative care utilization and outcomes among decedent patients with metastatic cancer in the U.S.

Jiazhang Xing, Folajimi J. Atunde, Haritha Gandicheruvu et al. Jun 01, 2026 pp. 11119-11119 10.1200/jco.2026.44.16_suppl.11119

11119 Background: Palliative care (PC) is a key component of high quality cancer care, especially at the end of life. Howe...

Demographics and trends of acute myeloid leukemia among young adults in the United States and Puerto Rico, 1999-2021.

Bishara Jahshan, Andy Veras Victoria, Syed Shahrukh Rizv Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18502

e18502 Background: We assessed racial and sex-related trends in deaths from Acute Myeloid Leukemia (AML) among US and Puer...

Study of the cytostatic effect of a new compound of the tropolon series on primary cultures of glioma cells.

Tatiana V. Chembarova, Nadezhda V. Gnennaya, Svetlana Yu Filippova et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14056

e14056 Background: Brain tumors present a genuine challenge for medicine due to their anatomical features, high resistance...

Early neutrophil incompetence following allogeneic stem cell transplant.

Maria Lampou, Sebastian Jusuf, Fateme Mirakhorli et al. Jun 01, 2026 pp. 6565-6565 10.1200/jco.2026.44.16_suppl.6565

6565 Background: Neutrophils are key immune effector cells against fungal pathogens such as Candida al...

Clinical outcomes with brexucabtagene autoleucel in refractory mantle cell lymphoma: A systematic review and single-arm meta-analysis with contextual comparison to lisocabtagene maraleucel.

Benyamin Alam, Amir Reza Akbari, Nawaz Z. Safdar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19010

e19010 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes for patients with refractory man...

Temporal trends in cardiovascular mortality among ovarian cancer patients in the United States: A 22-year analysis of United States mortality data by age, race, and geographic region, 1999-2020.

Jiss Joy, Hina Zubair, Anubhuti Sharma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17584

e17584 Background: Cardiovascular disease (CVD) represents a significant competing cause of death among ovarian cancer sur...

Same day/next day cancer care program: An early access program for patients with aggressive malignancies.

Artem Oganesyan, Tintu George, Melissa Hunt et al. Jun 01, 2026 pp. 11095-11095 10.1200/jco.2026.44.16_suppl.11095

11095 Background: Rapid referral of patients with suspected malignant disease to an oncology specialist is associated with...

<i>HER2</i> mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.

Gregory Gaughran, Vincent Caillet, Samuel J. Harris et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20673

e20673 Background: ERBB2 mutations ( HER2 mut) are an emerging...

Evaluating performance of an AI-based recurrence score in early breast cancer patients treated with chemoendocrine therapy: A secondary analysis of the UNIRAD trial.

Thomas Bachelot, Sylvie Chabaud, Jerome Lemonnier et al. Jun 01, 2026 pp. 550-550 10.1200/jco.2026.44.16_suppl.550

550 Background: Patients with node-positive HR+/HER2- early breast cancer are at high risk for relapse within 5 years of d...

Prediction of hematotoxicity using CT-derived body composition in rectal cancer patients receiving immunotherapy-based total neoadjuvant therapy.

Ruone Xu, Wang Yang, Xiaoming Sun et al. Jun 01, 2026 pp. 3599-3599 10.1200/jco.2026.44.16_suppl.3599

3599 Background: Immunotherapy-based total neoadjuvant therapy (iTNT) is a promising strategy to enhance complete response...

Empowering educators: An international virtual mentorship program for hematology/oncology medical educators.

Audrey M. Sigmund, Shivang Danak, Arianna Henning et al. Jun 01, 2026 pp. 9036-9036 10.1200/jco.2026.44.16_suppl.9036

9036 Background: Mentorship is a cornerstone of physician career development, linked to improved well-being, job satisfact...

Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data.

Hussein A. Tawbi, Dirk Schadendorf, Evan J. Lipson et al. Jun 01, 2026 pp. 9530-9530 10.1200/jco.2026.44.16_suppl.9530

9530 Background: An ITC comparing NIVO + RELA and NIVO + IPI, approved dual immunotherapy treatment options for patients (...

AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor ( <i>EGFR</i> )–mutated non–small cell lung cancer (NSCLC).

Adam Rock, Yi-Long Wu, Se-Hoon Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8661

TPS8661 Background: Patients with advanced EGFR -mutated NSCLC routinely receive t...

Exosomal miRNA signatures as predictors of response to neoadjuvant FOLFIRINOX and GEM/nab-paclitaxel in resectable pancreatic cancer: The PRECEPT study.

Takayuki Noma, Muhammad Anees, Erin Grayhack et al. Jun 01, 2026 pp. 4223-4223 10.1200/jco.2026.44.16_suppl.4223

4223 Background: Neoadjuvant chemotherapy (NAC) with FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM/nab-PTX) is widely...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page